Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03OFF
|
|||
| Former ID |
DAP000272
|
|||
| Drug Name |
Pioglitazone
|
|||
| Synonyms |
111025-46-8; Actos; Pioglitazona; Pioglitazonum; Glustin; Zactos; 105355-27-9; Pioglitazonum [INN-Latin]; Pioglitazona [INN-Spanish]; Duetact; Pioglitazone [INN:BAN]; Pioglitazone [BAN:INN]; 5-(4-(2-(5-ethylpyridin-2-yl)ethoxy)benzyl)thiazolidine-2,4-dione; AD-4833; U 72107; CHEBI:8228; Pioglitazone (Actos); HSDB 7322; Actos (TN); 5-{4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl}-1,3-thiazolidine-2,4-dione; C19H20N2O3S; AD 4833; 5-[4-[2-(5-ETHYL-2-PYRIDYL)ETHOXY]BENZYL]-2,4-THIAZOLIDINEDIONE; U 72107A; Actos; Actost; Glustin (TN); HS-0047; Pioglitazone (INN); U-72107; U72,107A; Zactos (TN); (+-)-5-((4-(2-(5-ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione; (+/-)-5-[[4-[2-(5-Ethyl-2-pyridinyl)-ethoxy]phenyl]methyl]-2,4-thiazolidinedione; (+/-)-5-[p-[2-(ethyl-2-pyridyl)ethoxy]benzyl]-2,4-thiazolidinedione; 2,4-Thiazolidinedione, 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-(9CI); 5-((4-(2-(5-Ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione; 5-(4-(2-(5-ethyl-2-pyridyl)ethoxy)benzyl)-2,4-thiazolidinedione; 5-[4-[2-(5-Ethyl-2-pyridyl)ethoxy]benzyl]thiazolidine-2,4-dione; 5-[[4-[2-(5-Ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-2,4-thiazolidinedione; 5-[[4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione; 5-[[4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl]methyl]thiazolidine-2,4-dione; 5-[[4-[2-[(5-ethyl-2-pyridyl)]ethoxy]phenyl]methyl]thiazolidine-2,4-dione; Linagliptin + pioglitazone; PCG1
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Diabetic complication [ICD-11: 5A2Y; ICD-9: 253.5, 588.1] | Approved | [1], [2] | |
| Type-2 diabetes [ICD-11: 5A11; ICD-9: 250] | Phase 3 | [3] | ||
| Obesity [ICD-11: 5B81; ICD-10: E66; ICD-9: 278] | Investigative | [4] | ||
| Therapeutic Class |
Hypoglycemic Agents
|
|||
| Company |
Takeda Pharmaceuticals
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C19H20N2O3S
|
|||
| Canonical SMILES |
CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3
|
|||
| InChI |
1S/C19H20N2O3S/c1-2-13-3-6-15(20-12-13)9-10-24-16-7-4-14(5-8-16)11-17-18(22)21-19(23)25-17/h3-8,12,17H,2,9-11H2,1H3,(H,21,22,23)
|
|||
| InChIKey |
HYAFETHFCAUJAY-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 111025-46-8
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
9877, 841973, 5514443, 7980327, 8152965, 10852019, 11364517, 11367079, 11369641, 11372042, 11374757, 11377803, 11485633, 11489495, 11490817, 11492944, 11495437, 14828061, 22395182, 26756476, 29223911, 46507136, 47359443, 47805056, 48403962, 49836649, 50052255, 50111371, 50830677, 53790062, 56311254, 56312043, 56313970, 56313978, 56314560, 57288465, 57288698, 57288809, 57322474, 81040922, 85789264, 92308830, 92712064, 96025064, 103181943, 103853946, 104307547, 117695425, 118855323, 124892398
|
|||
| ChEBI ID |
CHEBI:8228
|
|||
| ADReCS Drug ID | BADD_D01777 ; BADD_D01778 | |||
| SuperDrug ATC ID |
A10BG03
|
|||
| SuperDrug CAS ID |
cas=111025468
|
|||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Abundace of Studied Microbe(s) Regulated by Drug | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bacteroidales | ||||
|
Studied Microbe: Bacteroides
Show/Hide Hierarchy
|
[5] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | C57BL/6J mice | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Bacteroides was increased by Pioglitazone (p < 0.05). | |||
|
Studied Microbe: Bacteroides ovatus
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Bacteroides ovatus was decreased by Pioglitazone (adjusted p-values: 7.56E-04). | |||
|
Studied Microbe: Bacteroides xylanisolvens
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Bacteroides xylanisolvens was decreased by Pioglitazone (adjusted p-values: 7.05E-03). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bifidobacteriales | ||||
|
Studied Microbe: Bifidobacterium
Show/Hide Hierarchy
|
[5] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | C57BL/6J mice | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Bifidobacterium was increased by Pioglitazone (p < 0.05). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Lactobacillales | ||||
|
Studied Microbe: Lactobacillus
Show/Hide Hierarchy
|
[5] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | C57BL/6J mice | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Lactobacillus was decreased by Pioglitazone (p < 0.05). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Gut microbiota | ||||
|
Studied Microbe: Bacteroidetes
Show/Hide Hierarchy
|
[5] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | C57BL/6J mice | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Bacteroidetes was increased by Pioglitazone (p < 0.05). | |||
|
Studied Microbe: Firmicutes
Show/Hide Hierarchy
|
[5] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | C57BL/6J mice | Experimental Sample | Faeces | |
| Disease or Condition | Type 2 diabetes mellitus | |||
| Description | The abundance of Firmicutes was decreased by Pioglitazone (p < 0.05). | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2694). | |||
| REF 2 | Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes. Curr Drug Targets. 2009 Jan;10(1):71-87. | |||
| REF 3 | ClinicalTrials.gov (NCT01183013) 30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by a Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes for up to 54 Weeks. U.S. National Institutes of Health. | |||
| REF 4 | Obesity: pathophysiology and clinical management. Curr Med Chem. 2009;16(4):506-21. | |||
| REF 5 | Lactobacillus casei CCFM419 attenuates type 2 diabetes via a gut microbiota dependent mechanism. Food Funct. 2017 Sep 20;8(9):3155-3164. | |||
| REF 6 | Extensive impact of non-antibiotic drugs on human gut bacteria. Nature. 2018 Mar 29;555(7698):623-628. | |||
| REF 7 | Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas. Nat Med. 2002 Nov;8(11):1281-7. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.